Keywords: filgrastim, backed, new, indication, amgen-roche, recombinant, human
FILGRASTIM BACKED FOR NEW INDICATION
Article | 11 October 1993
Amgen-Roche's recombinant human granulocyte colony stimulating factor Neupogen/Granulokine (filgrastim) has received a unanimous recommendation from the European Community's regulatory ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
